With technology advancements dramatically improving the cost, accuracy, and time to map a person’s entire ... for people living with Duchenne muscular dystrophy amenable to exon 44 (DMD44).

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

a treatment for Duchenne muscular dystrophy or DMD in patients with exon 44 skipping amenable mutations. The company announced it has received authorization from the United Kingdom's Medicines and ...

Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025. Entrada Therapeutics, Inc. announced that it has received regulatory ...

Entrada Therapeutics has secured authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...

The authorization marks a significant step for Entrada, with CEO Dipal Doshi expressing the company's commitment to addressing the urgent needs of families affected by DMD. The upcoming trial will ...

CONNECT1 has enrolled two cohorts of boys and young men living with DMD amenable to exon 51 skipping and its endpoints include safety and tolerability, dystrophin production, exon skipping ...

The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...